Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Resumes China, India Inspections In Bid To Keep Drug Approvals On Schedule

Executive Summary

Agency’s struggle to meet user fee commitments despite travel restrictions expected to worsen as pandemic continues into 2021.

You may also be interested in...



GDUFA III: Some Goals May Be Measured In Business Days Instead Of Calendar Days

ANDA user fee goals likely would have to be reconfigured to account for business days and still maintain the intended length of time.

GDUFA III: Some Goals May Be Measured In Business Days Instead Of Calendar Days

ANDA user fee goals likely would have to be reconfigured to account for business days and still maintain the intended length of time.

US FDA's On-Time Review Decision Rates Slip During The Pandemic, Especially For Biosimilars

Likelihood of an on-time decision on a biosimilar application dropped significantly during the first nine months of the pandemic and declined a bit for new and generic drug applications. FDA says BsUFA review performance is function of program's small sample size.

Related Content

Topics

UsernamePublicRestriction

Register

PS143671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel